Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol

Ruth Gallily¹, Zhannah Yekhtin¹, Lumír Ondřej Hanuš²

¹The Lautenberg Center for General and Tumor Immunology, The Hadassah Medical School, The Hebrew University of Jerusalem, Jerusalem, Israel.
²Department of Medicinal and Natural Products, Institute for Drug Research, The Hadassah Medical School, The Hebrew University of Jerusalem, Jerusalem, Israel.

DOI: 10.4236/pp.2015.62010                

Abstract

Cannabidiol (CBD), a major constituent of Cannabis, has been shown to be a powerful anti-inflammatory and anti-anxiety drug, without exerting a psychotropic effect. However, when given either intraperitoneally or orally as a purified product, a bell-shaped dose-response was observed, which limits its clinical use. In the present study, we have studied in mice the anti-inflammatory and anti-nociceptive activities of standardized plant extracts derived from the Cannabis sativa L., clone 202, which is highly enriched in CBD and hardly contains any psychoactive ingredients. In stark contrast to purified CBD, the clone 202 extract, when given either intraperitoneally or orally, provided a clear correlation between the anti-inflammatory and anti-nociceptive responses and the dose, with increasing responses upon increasing doses, which makes this plant medicine ideal for clinical uses. The clone 202 extract reduced zymosan-induced paw swelling and pain in mice, and prevented TNFα production in vivo. It is likely that other components in the extract synergize with CBD to achieve the desired anti-inflammatory action that may contribute to overcoming the bell-shaped dose-response of purified CBD. We therefore propose that Cannabis clone 202 (Avidekel) extract is superior over CBD for the treatment of inflammatory conditions.

Keywords

Cannabis sativa L. Clone 202, Cannabidiol, Anti-Inflammation, Anti-Nociceptive, TNFα

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Hazekamp, A., Ware, M.A., Muller-Vahl, K.R., Abrams, D. and Grotenhermen, F. (2013) The Medicinal Use of Cannabis and Cannabinoids—An International Cross-Sectional Survey on Administration Forms. Journal of Psychoactive Drugs, 45, 199-210. http://dx.doi.org/10.1080/02791072.2013.805976
[2]	Mechoulam, R. (2012) Cannabis—A Valuable Drug That Deserves Better Treatment. Mayo Clinic Proceedings, 87, 107-109. http://dx.doi.org/10.1016/j.mayocp.2011.12.002
[3]	Greydanus, D.E., Hawver, E.K., Greydanus, M.M. and Merrick, J. (2013) Marijuana: Current Concepts. Frontiers in Public Health, 1, 42. http://dx.doi.org/10.3389/fpubh.2013.00042
[4]	Syed, Y.Y., McKeage, K. and Scott, L.J. (2014) Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis. Drugs, 74, 563-578. http://dx.doi.org/10.1007/s40265-014-0197-5
[5]	Brenneisen, R. (2007) Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents. Marijuana and the Cannabinoids, Chapter 2, 17-49. http://dx.doi.org/10.1007/978-1-59259-947-9_2
[6]	Pertwee, R.G. (2008) The Diverse CB1 and CB2 Receptor Pharmacology of Three Plant Cannabinoids: Delta9-Tetrahydrocannabinol, Cannabidiol and Delta9-Tetrahydrocannabivarin. British Journal of Pharmacology, 153, 199-215. http://dx.doi.org/10.1038/sj.bjp.0707442
[7]	Pacher, P. and Mechoulam, R. (2011) Is Lipid Signaling through Cannabinoid 2 Receptors Part of a Protective System? Progress in Lipid Research, 50, 193-211. http://dx.doi.org/10.1016/j.plipres.2011.01.001
[8]	Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R. and Feldmann, M. (2000) The Nonpsychoactive Cannabis Constituent Cannabidiol Is an Oral Anti-Arthritic Therapeutic in Murine Collagen-Induced Arthritis. Proceedings of the National Academy of Sciences USA, 97, 9561-9566. http://dx.doi.org/10.1073/pnas.160105897
[9]	Mechoulam, R., Peters, M., Murillo-Rodriguez, E. and Hanus, L.O. (2007) Cannabidiol—Recent Advances. Chemistry & Biodiversity, 4, 1678-1692. http://dx.doi.org/10.1002/cbdv.200790147
[10]	Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R. and Gallily, R. (2008) Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice. Neuropharmacology, 54, 244-249. http://dx.doi.org/10.1016/j.neuropharm.2007.06.029
[11]	Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben-Nun, A., Juknat, A. and Vogel, Z. (2011) Cannabidiol Inhibits Pathogenic T Cells, Decreases Spinal Microglial Activation and Ameliorates Multiple Sclerosis-Like Disease in C57BL/6 Mice. British Journal of Pharmacology, 163, 1507-1519. http://dx.doi.org/10.1111/j.1476-5381.2011.01379.x
[12]	Esposito, G., Filippis, D.D., Cirillo, C., Iuvone, T., Capoccia, E., Scuderi, C., Steardo, A., Cuomo, R. and Steardo, L. (2013) Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview. Phytotherapy Research, 27, 633-636. http://dx.doi.org/10.1002/ptr.4781
[13]	Jamontt, J.M., Molleman, A., Pertwee, R.G. and Parsons, M.E. (2010) The Effects of Delta-Tetrahydrocannabinol and Cannabidiol Alone and in Combination on Damage, Inflammation and in Vitro Motility Disturbances in Rat Colitis. British Journal of Pharmacology, 160, 712-723. http://dx.doi.org/10.1111/j.1476-5381.2010.00791.x
[14]	Gadó, K. and Gigler, G. (1991) Zymosan Inflammation: A New Method Suitable for Evaluating New Anti-Inflammatory Drugs. Agents and Actions, 32, 119-121. http://dx.doi.org/10.1007/BF01983335
[15]	Grotenhermen, F. (2003) Pharmacokinetics and Pharmacodynamics of Cannabinoids. Clinical Pharmacokinetics, 42, 327-360. http://dx.doi.org/10.2165/00003088-200342040-00003
[16]	Rocha, A.C., Fernandes, E.S., Quintao, N.L., Campos, M.M. and Calixto, J.B. (2006) Relevance of Tumour Necrosis Factor-Alpha for the Inflammatory and Nociceptive Responses Evoked by Carrageenan in the Mouse Paw. British Journal of Pharmacology, 148, 688-695. http://dx.doi.org/10.1038/sj.bjp.0706775
[17]	Romano, B., Borrelli, F., Pagano, E., Cascio, M.G., Pertwee, R.G. and Izzo, A.A. (2014) Inhibition of Colon Carcinogenesis by a Standardized Cannabis Sativa Extract with High Content of Cannabidiol. Phytomedicine, 21, 631-639. http://dx.doi.org/10.1016/j.phymed.2013.11.006
[18]	Capasso, R., Aviello, G., Borrelli, F., Romano, B., Ferro, M., Castaldo, L., Montanaro, V., Altieri, V. and Izzo, A.A. (2011) Inhibitory Effect of Standardized Cannabis Sativa Extract and Its Ingredient Cannabidiol on Rat and Human Bladder Contractility. Urology, 77, 1006.e9-1006e15. http://dx.doi.org/10.1016/j.urology.2010.12.006
[19]	De Petrocellis, L., Ligresti, A., Schiano Moriello, A., Iappelli, M., Verde, R., Stott, C.G., Cristino, L., Orlando, P. and Di Marzo, V. (2013) Non-THC Cannabinoids Inhibit Prostate Carcinoma Growth in Vitro and in Vivo: Pro-Apoptotic Effects and Underlying Mechanisms. British Journal of Pharmacology, 168, 79-102. http://dx.doi.org/10.1111/j.1476-5381.2012.02027.x
[20]	Russo, E.B. (2011) Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects. British Journal of Pharmacology, 163, 1344-1364. http://dx.doi.org/10.1111/j.1476-5381.2011.01238.x
[21]	Wagner, H. and Ulrich-Merzenich, G. (2009) Synergy Research: Approaching a New Generation of Phytopharmaceuticals. Phytomedicine, 16, 97-110. http://dx.doi.org/10.1016/j.phymed.2008.12.018